Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tetrathiomolybdate |
| Synonyms | |
| Therapy Description |
Tetrathiomolybdate depletes systemic copper, thereby inhibiting cuproenzymes and leading to antitumor effects (PMID: 26160923, PMID: 32005716). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tetrathiomolybdate | CCRIS 9412|ATN-224 | Tetrathiomolybdate depletes systemic copper, thereby inhibiting cuproenzymes and leading to antitumor effects (PMID: 26160923, PMID: 32005716). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01837329 | Phase I | Tetrathiomolybdate | Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer | Completed | USA | 0 |